FDA Approves Roche’s VENTANA MET (SP44) RxDx Assay as First Companion Diagnostic for Emrelis Treatment in NSCLC
SHERIDAN, WYOMING – May 27, 2025 – Roche has announced FDA approval of its VENTANA® MET (SP44) RxDx Assay, marking a major milestone in companion diagnostics for non-small cell lung cancer (NSCLC). This approval paves the way for a more precise identification of patients eligible for AbbVie’s Emrelis™ (telisotuzumab vedotin-tllv), a targeted therapy for non-squamous NSCLC with MET protein overexpression.
Enhancing Treatment Precision in Lung Cancer Care